Elke de Jong sits in her office at Radboud University Medical Center in the Netherlands with data that could transform the lives of half a million Dutch patients—and millions more worldwide—living with psoriasis. Her team, collaborating with researchers at Ghent University Hospital in Belgium, has just published findings showing that three-quarters of people who respond well to the newest biologic medications for psoriasis can safely cut their doses by as much as half without losing control of their symptoms.
For people with psoriasis, an inflammatory disease affecting skin, nails, and joints, these biologics have been genuinely life-changing. Over the past two decades, medications that inhibit interleukin-17 and interleukin-23 have dramatically reduced symptoms that once seemed permanent. But there's a catch: patients must take these medicines indefinitely, and the cost is staggering—around €17,000 per person per year for the newest formulations. That's where the new research matters most.
The study, published in The Lancet Regional Health—Europe, followed 244 patients across 19 hospitals in the Netherlands and Belgium for 18 months. Researchers gradually tapered doses under medical supervision, spacing out injections further apart. The results were unambiguous: in 75% of patients, lower doses worked just as well as standard ones. Some patients ended up needing injections only once every six months instead of every month or every other month.
The practical benefits cascade outward. Fewer injections mean fewer trips to the clinic, less risk of side effects, and less medication to produce and transport—a meaningful shift toward sustainability. Perhaps most significantly, the cost savings are substantial: reducing dosage can save up to €8,500 per patient annually. For healthcare systems stretched thin across Europe and beyond, that's not a minor detail.
Physician-epidemiologist Juul van den Reek emphasizes what made this study different from many clinical trials: it stayed true to real-world practice. Patients who felt anxious about reducing their medication could return to standard doses at any time. Many were understandably nervous. Some had lived with psoriasis symptoms for two decades before biologics offered relief, and the thought of losing that control felt risky. That pragmatic flexibility made the study's findings more convincing—these results reflect what patients would actually do in their own dermatologists' offices.
The biologics studied included secukinumab, ixekizumab, bimekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab, representing both major classes of modern psoriasis treatment. Researchers remain enthusiastic about these medications but now want to reshape how doctors think about using them. Jo Lambert, a professor at Ghent University Hospital, sees a clear path forward: "This first large prospective study involving many hospitals provides sufficient evidence to start adapting the guidelines in both the Netherlands and Belgium."
That shift—from fixed dosing to personalized, stepped-down treatment—represents a quiet but significant turn in how medicine addresses chronic disease. It acknowledges that not every patient needs the same dose indefinitely. It frees up healthcare resources. And it offers people living with psoriasis something equally valuable: fewer injections, fewer side effects, and the same quality of life they fought so hard to achieve.